Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-3,page-paged-3,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.5.0,vc_responsive

CLIENT NEWS

 

 

  • AiCuris AG Announces Dr. Stefan Oschmann, Former Merck CEO, to Chair the AiCuris Supervisory Board
    www.aicuris.com
  • Relief’s Partner Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA
    www.relieftherapeutics.com
  • Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3
    www.abivax.com
  • Tony Gibney Joins InflaRx Board of Directors
    www.inflarx.de
  • Tony Gibney Joins InflaRx Board of Directors
    www.inflarx.de
  • CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
    www.catalym.com
  • XPhyto Rapid Point-of-Care COVID-19 PCR Test Offered for Sale in Germany
    www.xphyto.com
  • Newron announces Paragraph IV ANDA filings for Xadago® (safinamide) in the USA
    www.newron.com
  • Relief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle Disorders
    www.relieftherapeutics.com
  • Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray
    www.relieftherapeutics.com